Rishi P. Singh, MD

A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.

A panel of ophthalmologists discuss strategies for managing AMD and DME patients who exhibit suboptimal responses to their current anti-VEGF therapy.

Retina specialists discuss treatment and adherence strategies for patients with nAMD and DME. They also comment on the future of nAMD and DME management.

Retina specialists discuss factors to consider when selecting a therapy for patients with neovascular AMD and DME as well as loading-dose recommendations for select patients.

Retina specialists comment on switching patients from 2 mg to 8 mg of aflibercept for the management of neovascular age-related macular degeneration and diabetic macular edema and transitioning a patient who has good control with aflibercept to a newer therapy.

Rishi P. Singh, MD; and Michael A. Klufas, MD, discuss how to gain both physician and patient trust when it comes to using biosimilars to treat ophthalmologic conditions.

Retina specialists highlight the safety data of both faricimab and high-dose aflibercept for use in treating nAMD and DME.

M. Ali Khan, MD, FACS, FASRS, reviews the PULSAR and PHOTON clinical trials of high-dose aflibercept for treatment of nAMD and DME.

Retina specialists review the current challenges with biosimilars in ophthalmology, commenting on insurance coverage and patient assistance programs.

Rishi P. Singh, MD; and Michael A. Klufas, MD, provide an overview of the 2 currently available ophthalmology biosimilars, ranibizumab-eqrn and ranibizumab-nuna, as well as discuss which patient populations will benefit from these treatments.

Rishi P. Singh, MD; and Michael A. Klufas, MD, comment on the reasoning behind a shorter primary end point for biosimilar studies.

Drs Rishi P. Singh and M. Ali Khan review the real-world experience of using faricimab to treat nAMD and DME, as well as its durability compared to clinical trials.

Rishi P. Singh, MD, and M. Ali Khan, MD, FACS, FASRS, discuss the need for extending treatment durability for neovascular age-related macular degeneration [nAMD] and diabetic macular edema [DME], as well as approaches to applying treat-and-extend strategies.

Michael A. Klufas, MD, discusses issues with off-label bevacizumab use, focusing on compounding issues and decreases in clinical efficacy due to repackaging.

Expert retina specialists review the impact of biosimilars in clinical ophthalmology practice, highlighting the potential decrease of financial burden to the patient.

Michael A. Klufas, MD, discusses the significance of interchangeability of biosimilars and being able to substitute biosimilars for reference products, as well as the path to achieving the designation of interchangeability from the FDA.

Rishi P. Singh, MD, and Michael A. Klufas, MD, provide an overview of the significance of and need for biosimilars in the ophthalmology space, and review the approval pathway for biosimilars.

Expert perspectives on the ongoing unmet needs in the management of macular edema following retinal vein occlusion.

Experts reflect on the role of steroids in macular edema following retinal vein occlusion and discuss the limited benefit of combination therapy.

Two experts discuss real-world treatment and observation of patients with macular edema after retinal vein occlusion.

Experts consider when they would use specific VEGF inhibitors for patients with macular edema following retinal vein occlusion.

Shared insight on clinical trial data in macular edema following retinal vein occlusion that support use of VEGF inhibition.

A broad scope of treatment options used in the management of macular edema following retinal vein occlusion.

A brief review of how the COVID-19 pandemic has impacted the identification of retinal vein occlusion for physicians and patients.

Comprehensive insight on optimal work-up and diagnostic testing for patients with retinal vein occlusion.

Experts define retinal vein occlusion and discuss risk factors, diagnostic testing, prognosis, and lifestyle modifications prevalent in the current paradigm.